Immunological Medicine最新文献_第2页

Emerging roles of checkpoint molecules on B cells. 检查点分子在B细胞中的新作用。

IF 2.9

Immunological Medicine Pub Date : 2025-09-01 Epub Date: 2025-01-17 DOI: 10.1080/25785826.2025.2454045

Hiromitsu Asashima, Satoshi Akao, Isao Matsumoto

引用次数: 0

Therapeutic potential of trained immunity for malignant disease. 训练免疫对恶性疾病的治疗潜力。

IF 2.9

Immunological Medicine Pub Date : 2025-09-01 Epub Date: 2024-12-05 DOI: 10.1080/25785826.2024.2438426

Hiroyuki Takahashi, Daibo Kojima, Masato Watanabe

{"title":"Therapeutic potential of trained immunity for malignant disease.","authors":"Hiroyuki Takahashi, Daibo Kojima, Masato Watanabe","doi":"10.1080/25785826.2024.2438426","DOIUrl":"10.1080/25785826.2024.2438426","url":null,"abstract":"Trained immunity (TI) is functional memory displayed by innate immune cells (IICs). TI facilitates rapid, non-specific responses to pathogens upon secondary challenge. It is driven by immunological signaling and metabolic rewriting via epigenetic alteration, triggered by recognition of certain stimuli. Recently, immune checkpoint inhibitors have come into common use in clinical oncology settings, and genetically engineered cytotoxic T cells comprise a potent cancer treatment strategy. However, the contributions of TI in the tumor microenvironment (TME) are only beginning to be uncovered. Accumulating evidence that various microorganisms and vaccines convey tumoricidal ability suggest that TI may become a useful anti-cancer tool. The expected roles of TI in tumor therapy are the 1) promotion of proinflammatory cytokine section, 2) enhancement of phagocytosis, 3) quick expansion and recruitment of cancer-specific cytotoxic T cells to the TME through neoantigen presentation, 4) reversal of immunosuppression in the TME, and 5) removal of pathogens associated with carcinogenesis or tumor development. Medium- to long-term TI durability may reduce the risk of tumor development. Recent findings on TI usher in new aspirations for cancer treatment.","PeriodicalId":37286,"journal":{"name":"Immunological Medicine","volume":" ","pages":"149-160"},"PeriodicalIF":2.9,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142787353","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The role of TRECs/KRECs as immune indicators that reflect immunophenotypes and predict the risk of infection in systemic autoimmune diseases. TRECs/KRECs作为反映免疫表型和预测全身自身免疫性疾病感染风险的免疫指标的作用

IF 2.9

Immunological Medicine Pub Date : 2025-09-01 Epub Date: 2025-02-03 DOI: 10.1080/25785826.2025.2460275

Takuji Itakura, Hirokazu Sasaki, Tadashi Hosoya, Natsuka Umezawa, Tetsuya Saito, Hideyuki Iwai, Hisanori Hasegawa, Hiroyuki Sato, Akihiro Hirakawa, Kohsuke Imai, Tomohiro Morio, Naoki Kimura, Shinsuke Yasuda

{"title":"The role of TRECs/KRECs as immune indicators that reflect immunophenotypes and predict the risk of infection in systemic autoimmune diseases.","authors":"Takuji Itakura, Hirokazu Sasaki, Tadashi Hosoya, Natsuka Umezawa, Tetsuya Saito, Hideyuki Iwai, Hisanori Hasegawa, Hiroyuki Sato, Akihiro Hirakawa, Kohsuke Imai, Tomohiro Morio, Naoki Kimura, Shinsuke Yasuda","doi":"10.1080/25785826.2025.2460275","DOIUrl":"10.1080/25785826.2025.2460275","url":null,"abstract":"T cell receptor rearrangement excision circles (TRECs) and immunoglobulin κ-deleting recombination excision circles (KRECs) represent the lymphopoiesis capacity, widely used for newborn screening of inborn errors of immunity. To clarify the significance of TRECs and KRECs as immune indicators in patients with systemic autoimmune diseases, we prospectively evaluated TREC and KREC levels with qPCR, lymphocyte phenotypes with flow cytometry, along with lymphocyte counts and serum immunoglobulin levels in peripheral blood samples from newly diagnosed patients. Each variable was assessed before immunosuppressive treatments (baseline), 3-, 6-, and 12-months after the treatment. Severe infections were recorded until 6 months after treatment. Among 35 patients, TREC and KREC levels were associated positively with the proportion of recent thymic emigrants, naïve T and B cells at all the timepoints. TREC and KREC levels decreased after treatment. The ratios of TREC and KREC levels under treatment to baseline were significantly lower in patients with severe infection than those without. In conclusion, TREC and KREC levels reflect peripheral blood immunophenotypes, specifically recent-emigrated T and B cells, in patients under treatment-naïve and immunosuppressive conditions. The longitudinal changes in TREC and KREC levels were beneficial markers for predicting the risk of severe infection during immunosuppressive treatments.","PeriodicalId":37286,"journal":{"name":"Immunological Medicine","volume":" ","pages":"233-244"},"PeriodicalIF":2.9,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143081444","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Additional benefits of belimumab in chronic phase of systemic lupus erythematosus and efficacy of tacrolimus combination therapy. 贝利姆单抗在系统性红斑狼疮慢性期的额外益处和他克莫司联合治疗的疗效。

IF 2.9

Immunological Medicine Pub Date : 2025-09-01 Epub Date: 2024-12-27 DOI: 10.1080/25785826.2024.2447629

Satoshi Suzuki, Tomoya Otani, Keigo Ikeda, Naoto Tamura, Shinji Morimoto

{"title":"Additional benefits of belimumab in chronic phase of systemic lupus erythematosus and efficacy of tacrolimus combination therapy.","authors":"Satoshi Suzuki, Tomoya Otani, Keigo Ikeda, Naoto Tamura, Shinji Morimoto","doi":"10.1080/25785826.2024.2447629","DOIUrl":"10.1080/25785826.2024.2447629","url":null,"abstract":"Systemic lupus erythematosus (SLE) is a typical autoimmune disease; although severe disease and refractoriness to existing therapies are still experienced, the number of cases resistant to remission induction has decreased with the establishment of various therapies. However, improving long-term prognosis remains a challenge due to the unavoidable prolonged use of non-selective glucocorticoids. To investigate the additional effect of belimumab in the chronic phase, we included 28 of 46 patients with SLE who were initiated on belimumab between January 2018 and October 2022 for glucocorticoid reduction. The efficacy of tacrolimus and mycophenolate mofetil in combination with belimumab was also compared. In the stable chronic phase, the combination with belimumab improved the SLE Disease Activity Index and reduced glucocorticoid requirement. The tacrolimus with belimumab group was not significantly inferior to the mycophenolate mofetil with belimumab group and was effective in treatment and glucocorticoid sparing including cases at all phases of SLE. To improve the long-term prognosis of SLE, it is crucial to introduce highly selective biological agents and reduce glucocorticoids whenever possible. Belimumab is effective with or without hydroxychloroquine and Tac was effective as concomitant drugs.","PeriodicalId":37286,"journal":{"name":"Immunological Medicine","volume":" ","pages":"219-225"},"PeriodicalIF":2.9,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142899013","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Characteristic TARC/CCL17 expression in the salivary gland of IgG4-related disease: potential diagnostic utility and insights into pathogenesis. IgG4 相关疾病唾液腺中 TARC/CCL17 的特征性表达：潜在的诊断作用和对发病机制的见解。

IF 2.9

Immunological Medicine Pub Date : 2025-09-01 Epub Date: 2025-02-04 DOI: 10.1080/25785826.2025.2460910

Nanako Kikuchi, Sae Hatanaka, Terufumi Kubo, Ryuta Kamekura, Masatoshi Kanda, Takuya Kakuki, Takashi Sasaya, Kengo Mita, Hiroki Kobayashi, Hajime Ikai, Kenta Sasaki, Naoki Shijubou, Kenji Murata, Takayuki Kanaseki, Tomohide Tsukahara, Yoshihiko Hirohashi, Tadashi Hasegawa, Akihiro Miyazaki, Hiroki Takahashi, Ken-Ichi Takano, Toshihiko Torigoe

{"title":"Characteristic TARC/CCL17 expression in the salivary gland of IgG4-related disease: potential diagnostic utility and insights into pathogenesis.","authors":"Nanako Kikuchi, Sae Hatanaka, Terufumi Kubo, Ryuta Kamekura, Masatoshi Kanda, Takuya Kakuki, Takashi Sasaya, Kengo Mita, Hiroki Kobayashi, Hajime Ikai, Kenta Sasaki, Naoki Shijubou, Kenji Murata, Takayuki Kanaseki, Tomohide Tsukahara, Yoshihiko Hirohashi, Tadashi Hasegawa, Akihiro Miyazaki, Hiroki Takahashi, Ken-Ichi Takano, Toshihiko Torigoe","doi":"10.1080/25785826.2025.2460910","DOIUrl":"10.1080/25785826.2025.2460910","url":null,"abstract":"Immunoglobulin G4-related disease (IgG4-RD) is a chronic inflammatory condition of unknown etiology characterized by lymphocytic infiltration, fibrosis, and infiltration of IgG4-positive plasma cells. It affects various organs, including the pancreas and salivary glands. Immunological abnormalities are suspected to play a role in its pathogenesis, and there is an epidemiological link to allergic conditions and type 2 inflammation. This study focused on the expression of thymus and activation-regulated chemokine (TARC)/CCL17, which is involved in the migration of T helper 2 and/or regulatory T cells, in salivary gland tissues of patients with IgG4-RD. We analyzed 60 salivary gland biopsy samples obtained from patients at Sapporo Medical University Hospital between 2015 and 2020. Immunohistochemical analysis revealed TARC/CCL17 positivity in 87.2% of histologically confirmed IgG4-RD cases and negativity in 84.6% of histologically unconfirmed but clinically suspected IgG4-RD cases. There was a significant correlation between histologically confirmed IgG4-RD and TARC/CCL17 expression, suggesting its potential diagnostic utility and possible involvement in the pathogenesis of IgG4-RD.","PeriodicalId":37286,"journal":{"name":"Immunological Medicine","volume":" ","pages":"226-232"},"PeriodicalIF":2.9,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143190815","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effectiveness for remission maintenance rate and safety of different rituximab regimens for treating anti-neutrophil cytoplasmic antibody-associated vasculitis in Japan: a J-CANVAS study. 日本不同利妥昔单抗方案治疗抗中性粒细胞细胞质抗体相关血管炎的缓解维持率和安全性：J-CANVAS研究

IF 2.9

Immunological Medicine Pub Date : 2025-09-01 Epub Date: 2025-01-11 DOI: 10.1080/25785826.2024.2448912

Chie Ogita, Kazuteru Noguchi, Jiro Takeuchi, Naoto Azuma, Satoshi Omura, Daiki Nakagomi, Yoshiyuki Abe, Masatoshi Kadoya, Naoho Takizawa, Atsushi Nomura, Yuji Kukida, Naoya Kondo, Yasuhiko Yamano, Takuya Yanagida, Koji Endo, Shintaro Hirata, Tohru Takeuchi, Kunihiro Ichinose, Masaru Kato, Ryo Yanai, Yusuke Matsuo, Yasuhiro Shimojima, Ryo Nishioka, Ryota Okazaki, Tomoaki Takata, Takafumi Ito, Mayuko Moriyama, Ayuko Takatani, Yoshia Miyawaki, Yutaka Kawahito, Toshiko Ito-Ihara, Takashi Kida, Nobuyuki Yajima, Takashi Kawaguchi, Kiyoshi Matsui

{"title":"Effectiveness for remission maintenance rate and safety of different rituximab regimens for treating anti-neutrophil cytoplasmic antibody-associated vasculitis in Japan: a J-CANVAS study.","authors":"Chie Ogita, Kazuteru Noguchi, Jiro Takeuchi, Naoto Azuma, Satoshi Omura, Daiki Nakagomi, Yoshiyuki Abe, Masatoshi Kadoya, Naoho Takizawa, Atsushi Nomura, Yuji Kukida, Naoya Kondo, Yasuhiko Yamano, Takuya Yanagida, Koji Endo, Shintaro Hirata, Tohru Takeuchi, Kunihiro Ichinose, Masaru Kato, Ryo Yanai, Yusuke Matsuo, Yasuhiro Shimojima, Ryo Nishioka, Ryota Okazaki, Tomoaki Takata, Takafumi Ito, Mayuko Moriyama, Ayuko Takatani, Yoshia Miyawaki, Yutaka Kawahito, Toshiko Ito-Ihara, Takashi Kida, Nobuyuki Yajima, Takashi Kawaguchi, Kiyoshi Matsui","doi":"10.1080/25785826.2024.2448912","DOIUrl":"10.1080/25785826.2024.2448912","url":null,"abstract":"Rituximab (RTX) has been reported to effectively maintain remission in anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV). In this multicenter study involving 57 patients who achieved remission after 24 weeks, we evaluated the effectiveness of RTX in maintaining remission in patients with AAV. Patients were divided into three groups based on RTX administration: continuous, induction phase-only, and maintenance phase-only groups. The continuous group had a remission maintenance rate after 48 weeks of treatment compared with the induction phase-only group (100% vs. 88.2%, p = 0.29). More patients in the continuous group received three or more RTX doses during the induction period (82.4% vs. 52.9%, p = 0.06), and this group had a lower incidence of infection (5.9% vs. 29.4%, p = 0.08). Compared with the maintenance-only group, the continuous group had a numerically higher proportion of patients in remission after 48 weeks of treatment (100% vs. 83.3%, p = 0.26) and a lower incidence of infection (5.9% vs. 50%, p = 0.04); however, the N in the maintenance phase was small and suspected to have low power. Regardless of the method of RTX administration (induction phase-only or continuous), administering RTX during the induction phase may be crucial for achieving remission.","PeriodicalId":37286,"journal":{"name":"Immunological Medicine","volume":" ","pages":"203-210"},"PeriodicalIF":2.9,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142967218","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Chronic kidney disease and inflammatory cytokines in rheumatoid arthritis: a potential pathogenic link. 慢性肾脏疾病和类风湿关节炎中的炎性细胞因子：潜在的致病联系。

IF 2.9

Immunological Medicine Pub Date : 2025-09-01 Epub Date: 2025-01-31 DOI: 10.1080/25785826.2025.2460267

Hironari Hanaoka, Takumi Aoki, Taiji Kosaka, Shoichi Yoshinaga, Akiko Shibata, Ryota Sakai, Takahiko Kurasawa, Koichi Amano

{"title":"Chronic kidney disease and inflammatory cytokines in rheumatoid arthritis: a potential pathogenic link.","authors":"Hironari Hanaoka, Takumi Aoki, Taiji Kosaka, Shoichi Yoshinaga, Akiko Shibata, Ryota Sakai, Takahiko Kurasawa, Koichi Amano","doi":"10.1080/25785826.2025.2460267","DOIUrl":"10.1080/25785826.2025.2460267","url":null,"abstract":"Recent evidence indicates an increased risk of chronic kidney disease (CKD) in patients with rheumatoid arthritis (RA), with prevalence rates ranging from 20.8% to 24.5%. Risk factors for CKD among RA patients include advancing age, diabetes, cardiovascular disease, hypertension and RA disease activity. Medications such as glucocorticoids and nonsteroidal anti-inflammatory drugs (NSAIDs) may also accelerate CKD progression. Inflammatory cytokines, notably interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α) and IL-1, play significant roles in the pathogenesis of both RA and CKD, promoting systemic inflammation and renal impairment. Elevated levels of various cytokines have been detected in the plasma and urine of CKD patients, and they raise morbidity and mortality rates, even during early disease stages. Effective management of RA activity and modifications in treatment to reduce renal burden are essential for lowering CKD risk and improving patient outcomes. Biological disease-modifying antirheumatic drugs (DMARDs), particularly those targeting IL-6 and TNF-α, show potential in mitigating CKD progression in RA patients. However, individualized treatment and careful kidney function monitoring are critical, as CKD may impact RA management. Future research should focus on therapeutic strategies that address inflammation in both RA and CKD to optimize patient care.","PeriodicalId":37286,"journal":{"name":"Immunological Medicine","volume":" ","pages":"161-170"},"PeriodicalIF":2.9,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143068582","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Analysis of musculoskeletal ultrasound findings and cytokines/growth factors in glucocorticoid-resistant polymyalgia rheumatica. 糖皮质激素耐受性多发性风湿性关节炎的肌肉骨骼超声检查结果和细胞因子/生长因子分析。

IF 2.9

Immunological Medicine Pub Date : 2025-09-01 Epub Date: 2024-11-19 DOI: 10.1080/25785826.2024.2429906

Tomoki Origuchi, Masataka Umeda, Shoichi Fukui, Kaori Furukawa, Toshimasa Shimizu, Remi Sumiyoshi, Tomohiro Koga, Shin-Ya Kawashiri, Naoki Iwamoto, Mami Tamai, Kazuhiko Arima, Atsushi Kawakami

{"title":"Analysis of musculoskeletal ultrasound findings and cytokines/growth factors in glucocorticoid-resistant polymyalgia rheumatica.","authors":"Tomoki Origuchi, Masataka Umeda, Shoichi Fukui, Kaori Furukawa, Toshimasa Shimizu, Remi Sumiyoshi, Tomohiro Koga, Shin-Ya Kawashiri, Naoki Iwamoto, Mami Tamai, Kazuhiko Arima, Atsushi Kawakami","doi":"10.1080/25785826.2024.2429906","DOIUrl":"10.1080/25785826.2024.2429906","url":null,"abstract":"We sought to clarify the musculoskeletal ultrasound (MSUS) findings and serum concentrations of cytokines/growth factors in glucocorticoid-resistant polymyalgia rheumatica (GC-R PMR). Patients with PMR admitted to Nagasaki University Hospital (n = 41) were enrolled. MSUS of both shoulder joints was performed in 36 patients. Patients' sera were analyzed for cytokines/growth factors using multiplex assay kits. We examined the cases of 17 males and 24 females (median age 70 years). There were 27 GC-R patients and 14 non-GC-R patients. PD signals were detected in significantly more GC-R patients (65.2%) than non-GC-R patients (23.1%) (p = 0.035). The median serum level of vascular endothelial growth factor (VEGF) was significantly higher in the GC-R group at 871.4 pg/mL than the non-GC-R group (422.8 pg/mL) (p = 0.03) and significantly higher in the PD-positive versus PD-negative patients (p = 0.04). A multivariate analysis revealed that a high serum VEGF level was an independent variable contributing to GC resistance (p = 0.017, odds ratio: 10.34). These results suggest that a high serum VEGF level is a biomarker of GC resistance in PMR, which might be explained by PD-positive neovascularization in inflamed joints of PMR.","PeriodicalId":37286,"journal":{"name":"Immunological Medicine","volume":" ","pages":"211-218"},"PeriodicalIF":2.9,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142669255","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A novel frameshift mutation in ADCK1 identified in a case of chronic fatigue syndrome successfully treated with oral 5-ALA/SFC. 在口服5-ALA/SFC成功治疗慢性疲劳综合征的病例中发现了ADCK1的新移码突变。

IF 2.9

Immunological Medicine Pub Date : 2025-09-01 Epub Date: 2024-12-26 DOI: 10.1080/25785826.2024.2445399

Tomohiro Koga, Kiyoshi Kita, Junko Okumura, Koh-Ichiro Yoshiura, Atsushi Kawakami

{"title":"A novel frameshift mutation in ADCK1 identified in a case of chronic fatigue syndrome successfully treated with oral 5-ALA/SFC.","authors":"Tomohiro Koga, Kiyoshi Kita, Junko Okumura, Koh-Ichiro Yoshiura, Atsushi Kawakami","doi":"10.1080/25785826.2024.2445399","DOIUrl":"10.1080/25785826.2024.2445399","url":null,"abstract":"Chronic Fatigue Syndrome (CFS) is a complex disorder characterized by prolonged, unexplained fatigue and challenging diagnosis. We report the case of a 35-year-old Japanese woman with CFS who had experienced chronic fatigue since the age of 11 years. Despite treatment with modafinil, methylphenidate, levocarnitine, and ubiquinone, the symptoms persisted. Introduction of oral 5-aminolevulinic acid with sodium ferrous citrate (5-ALA/SFC) led to significant improvements in daily activities, mobility, and psychosocial functioning. Genetic analysis revealed a novel heterozygous frameshift deletion in ADCK1 (p.Asn280fs), a gene related to mitochondrial function, which was confirmed using cDNA sequencing. ADCK1 deficiency has been associated with developmental disabilities, mitochondrial dysfunction, increased reactive oxygen species levels, and apoptosis in Drosophila and muscle cells. This case supports the hypothesis that ADCK1 mutations contribute to mitochondrial dysfunction and CFS pathogenesis. The patient's significant clinical improvement with 5-ALA/SFC and ubiquinone suggests their potential for addressing mitochondrial dysfunction. Further functional and familial analyses are required to confirm the role of this heterozygous ADCK1 mutation in CFS. This case highlights the importance of considering mitochondrial dysfunction in CFS, and the potential therapeutic benefits of 5-ALA/SFC and ubiquinone.","PeriodicalId":37286,"journal":{"name":"Immunological Medicine","volume":" ","pages":"251-255"},"PeriodicalIF":2.9,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142899010","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pyoderma gangrenosum arising at the site of BCG immunization in a nine-month-old girl. 一个9个月大的女婴在接种卡介苗部位出现坏疽性脓皮病。

IF 2.9

Immunological Medicine Pub Date : 2025-09-01 Epub Date: 2024-12-26 DOI: 10.1080/25785826.2024.2445388

Yuka Okura, Yasuyoshi Hiramatsu, Masaki Shimomura, Kota Taniguchi, Mitsuru Nawate, Yutaka Takahashi, Masahiro Ueki, Shunichiro Takezaki, Ichiro Kobayashi

{"title":"Pyoderma gangrenosum arising at the site of BCG immunization in a nine-month-old girl.","authors":"Yuka Okura, Yasuyoshi Hiramatsu, Masaki Shimomura, Kota Taniguchi, Mitsuru Nawate, Yutaka Takahashi, Masahiro Ueki, Shunichiro Takezaki, Ichiro Kobayashi","doi":"10.1080/25785826.2024.2445388","DOIUrl":"10.1080/25785826.2024.2445388","url":null,"abstract":"Pyoderma gangrenosum (PG) is an extremely rare disorder in children. We report a nine-month-old girl with PG who presented with high-grade fever and rapidly progressive ulcers at the site of a Bacillus Calmette-Guérin (BCG) inoculation 2 months after the immunization. Additional small pustules developed on her hand and posterior neck three months after the immunization and rapidly progressed. Cytokine profiling demonstrated elevated serum levels of interleukin (IL)-1β, IL-10, IL-17A, IL-6 and IL-18, which is similar to adult cases. Genetic analysis identified heterozygous R202Q variant of the MEFV gene. All of her systemic and local symptoms responded to intravenous methylprednisolone pulse therapy followed by prednisolone 2 mg/kg/day. There is no relapse of PG, to date, even after discontinuation of prednisolone. Atypical skin reactions after a BCG immunization could be an initial manifestation of infantile PG and need attention. Similarity of cytokine profile suggests common pathophysiology of infantile and adult PG.","PeriodicalId":37286,"journal":{"name":"Immunological Medicine","volume":" ","pages":"245-250"},"PeriodicalIF":2.9,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142899016","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0